Information Provided By:
Fly News Breaks for June 15, 2018
BGNE
Jun 15, 2018 | 13:00 EDT
After BeiGene presented results on its investigational BTK inhibitor zanubrutinib at the EHA meeting, Piper Jaffray analyst Tyler Van Buren said the update suggests zanubrutinib is "at least in line with" the other BTKs and has potential for eventual differentiation. He was encouraged to see a significant increase in the complete response rate for mantle cell lymphoma and thinks the data will support an approval in China next year, he tells investors. Van Buren keeps an Overweight rating and $200 price target on BeiGene shares.